CN105566437B - 一种8dm衍生物及利用其合成糠酸莫米松的方法 - Google Patents
一种8dm衍生物及利用其合成糠酸莫米松的方法 Download PDFInfo
- Publication number
- CN105566437B CN105566437B CN201511024203.5A CN201511024203A CN105566437B CN 105566437 B CN105566437 B CN 105566437B CN 201511024203 A CN201511024203 A CN 201511024203A CN 105566437 B CN105566437 B CN 105566437B
- Authority
- CN
- China
- Prior art keywords
- compound
- derivatives
- reaction
- momestasone furoate
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 50
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229940125782 compound 2 Drugs 0.000 claims abstract description 17
- 229940126214 compound 3 Drugs 0.000 claims abstract description 12
- 238000005660 chlorination reaction Methods 0.000 claims abstract description 4
- 238000007142 ring opening reaction Methods 0.000 claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 87
- 239000007788 liquid Substances 0.000 claims description 38
- 239000012074 organic phase Substances 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 229960000583 acetic acid Drugs 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000012065 filter cake Substances 0.000 claims description 7
- 239000012362 glacial acetic acid Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 4
- 238000010189 synthetic method Methods 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 abstract description 27
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 2
- 230000032050 esterification Effects 0.000 abstract description 2
- 238000005886 esterification reaction Methods 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 238000004321 preservation Methods 0.000 description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 150000002118 epoxides Chemical class 0.000 description 4
- -1 p-toluenesulfonyl Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001993 dienes Chemical class 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
- 229960001664 mometasone Drugs 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical class CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511024203.5A CN105566437B (zh) | 2015-12-30 | 2015-12-30 | 一种8dm衍生物及利用其合成糠酸莫米松的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511024203.5A CN105566437B (zh) | 2015-12-30 | 2015-12-30 | 一种8dm衍生物及利用其合成糠酸莫米松的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105566437A CN105566437A (zh) | 2016-05-11 |
CN105566437B true CN105566437B (zh) | 2018-07-20 |
Family
ID=55877124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511024203.5A Active CN105566437B (zh) | 2015-12-30 | 2015-12-30 | 一种8dm衍生物及利用其合成糠酸莫米松的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105566437B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279340B (zh) * | 2016-08-10 | 2018-07-20 | 山东京卫制药有限公司 | 一种合成糠酸莫米松或其一水合物的方法 |
CN108129537B (zh) * | 2017-12-19 | 2022-03-01 | 广州健康元呼吸药物工程技术有限公司 | 一种糖皮质激素异构体及其制备方法和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT923599E (pt) * | 1996-06-28 | 2002-06-28 | Schering Corp | Processo para a preparacao de 17-esteres de 9alfa,21-di-halopregnano-11beta,17alfadiol-20-onas |
NZ500555A (en) * | 1999-08-02 | 2000-11-24 | Hovione Int Ltd | Process for the preparation of mometasone furoate |
CN1137899C (zh) * | 2000-03-16 | 2004-02-11 | 上海华联制药有限公司 | 17,21-酯取代的1,4-二烯-3-酮-9,11-环氧甾体化合物 |
-
2015
- 2015-12-30 CN CN201511024203.5A patent/CN105566437B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN105566437A (zh) | 2016-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106279340B (zh) | 一种合成糠酸莫米松或其一水合物的方法 | |
CN105481933B (zh) | 一种合成糠酸莫米松的方法 | |
US5063222A (en) | Antiinflammatory dexamethasone 17α-cyclopropanecarboxylates with reduced systemic activity | |
EP3642217A1 (en) | Methods and intermediates for the preparation of bile acid derivatives | |
JP6151453B2 (ja) | 1−[(2−ブロモフェニル)スルホニル]−5−メトキシ−3−[(4−メチル−1−ピペラジニル)メチル]−1h−インドールジメシラート一水和物の大規模合成法 | |
BR112014031828B1 (pt) | Composições farmacêuticas compreendendo a forma 1 de ácido obeticólico | |
JP2009138000A (ja) | アミノステロール、ビタミンd類似体および他の化合物の製造に有用な24−ヒドロキシル化された化合物の立体選択的合成 | |
BRPI0517752B1 (pt) | processo para a preparação de drospirenona | |
CN105566437B (zh) | 一种8dm衍生物及利用其合成糠酸莫米松的方法 | |
CN104447934B (zh) | 一种醋酸阿比特龙的纯化方法 | |
CN106397519A (zh) | 一种烯丙孕素的制备方法 | |
JPH03178977A (ja) | ジテルペンラクトン化合物及びその製造方法 | |
CN105884644A (zh) | 一种中性内肽酶抑制剂盐优势形态及其制备方法 | |
CN105622696A (zh) | 一种乳化浸取法纯化去氢表雄酮的方法 | |
CN103421070A (zh) | 一种改进的孕甾烯类化合物c21-乙酰氧基化方法 | |
CN103396371A (zh) | 一种盐酸埃罗替尼晶型a的制备方法 | |
JP2019509293A (ja) | 4−ペンタフルオロチオフェノール類化合物と調製方法及びペンタフルオロサルファー置換ベンゾピラン化合物の調製方法 | |
CN110372706A (zh) | 一种抗肿瘤药物瑞博西尼中间体的合成方法 | |
CN108129537B (zh) | 一种糖皮质激素异构体及其制备方法和用途 | |
CN102558273A (zh) | 氟替卡松糠酸酯的制备方法 | |
JP2000026365A (ja) | シキミ酸およびその誘導体の製造方法 | |
CN104387435B (zh) | 一种化合物及其制备方法与应用 | |
CN105753747B (zh) | 一种制备高纯度多库酯钠peg溶液的工业化生产新方法 | |
CN110078784A (zh) | 一种布地奈德杂质usp-z1的合成方法 | |
JPS5927360B2 (ja) | ステロイド化合物およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to an 8dm derivative and a method for synthesizing mometasone furoate using the derivative Effective date of registration: 20211230 Granted publication date: 20180720 Pledgee: Industrial Bank Co.,Ltd. Tai'an Branch Pledgor: JEWIM PHARMACEUTICAL (SHANDONG) CO.,LTD. Registration number: Y2021980016939 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230203 Granted publication date: 20180720 Pledgee: Industrial Bank Co.,Ltd. Tai'an Branch Pledgor: JEWIM PHARMACEUTICAL (SHANDONG) CO.,LTD. Registration number: Y2021980016939 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A 8DM derivative and a method for synthesizing mometasone furoate from it Effective date of registration: 20230210 Granted publication date: 20180720 Pledgee: Industrial Bank Co.,Ltd. Tai'an Branch Pledgor: JEWIM PHARMACEUTICAL (SHANDONG) CO.,LTD. Registration number: Y2023980032425 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20180720 Pledgee: Industrial Bank Co.,Ltd. Tai'an Branch Pledgor: JEWIM PHARMACEUTICAL (SHANDONG) CO.,LTD. Registration number: Y2023980032425 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A derivative of 8DM and a method for synthesizing mometasone furoate using it Granted publication date: 20180720 Pledgee: Industrial Bank Co.,Ltd. Tai'an Branch Pledgor: JEWIM PHARMACEUTICAL (SHANDONG) CO.,LTD. Registration number: Y2024980004981 |